Skip to main content
. 2017 Aug 7;7:7405. doi: 10.1038/s41598-017-07565-2

Figure 3.

Figure 3

IKK2 inhibitors enhance GR activity. (A) IKK2 inhibitors enhance NF-κB repression by GR. The reporter cells were treated with 5 ng/mL IL-1β ± 0.5 nM Dex, and inhibitors as indicated for 18 h. Luciferase assays were performed, and NF-κB repression was calculated relative to the cells treated with IL1β. The synergy ratio is shown. (B,C) TPCA-1 enhances IL-6 release inhibition by GR. A549 cells (B) or human airway smooth muscle cells (C) were treated as in (A), and the level of IL-6 in medium was assayed by ELISA. (D) IKK2 inhibitor enhances trans-activation by GR. A549 cells were transfected with pGILZ-luc plasmid for 48 h, and then2.5 nM Dex and TPCA-1 were added as indicated. After 18 h treatment, luciferase assays were performed. (E) A549 cells were treated with 0.8 μM TPCA-1 and 2.5 nM Dex for 18 h, and qPCR was used to measure GILZ expression. The relative mRNA levels are shown. *P < 0.05. **P < 0.01, ***P < 0.005.